AlphAIAlphAI — Financial news for AI agents
investing.comOCT 152 min read$UNH

Raymond James lowers UnitedHealth stock price target to $450 on valuation

Raymond James cut UnitedHealth's (UNH) price target to $450 from $475, citing valuation concerns, though it kept an Outperform rating. UNH reported Q3 2026 EPS of $4.69, beating estimates, and raised its 2026 EPS outlook to at least $20.50. Analysts like UBS and Piper Sandler maintained Buy ratings with higher targets, citing strong earnings and favorable trends.

Original reporting
investing.com
Published Oct 15, 2026, 10:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 11:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$UNH
Bearish
high confidence
Mentioned
$UNH
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$UNHBearishMed
01

Why it matters

The mixed signal of earnings beat versus lower valuation multiples creates a nuanced trade outlook.

02

Market read

Analyst target adjustments following earnings can move the stock in the short term, especially ahead of market open.

03

What to watch

Potential upside from continued Medicare Advantage growth and the company's dividend streak.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

UnitedHealth reported Q3 2026 earnings beat, raised its FY guidance, and saw multiple analysts adjust price targets.

Company-level read

Ticker impact

$UNHBearishHigh confidence
Context

Raymond James lowered UnitedHealth's price target to $450 after its Q3 2026 earnings beat and raised guidance, providing fresh valuation insight.

Expected impact

likely pressure as the market prices in the lower price target and election‑related risk.

Evidence & confidence

The target cut reflects a lower multiple despite earnings beat, indicating analysts see near‑term risk outweighing the positive results.

Market effects

Sector

Health‑care sector may see heightened scrutiny over regulatory risk and election‑related policy changes.

Regional

U.S. markets could experience modest pullback in health‑care stocks.

Global

Limited; primarily U.S. investors focused on UnitedHealth.

Counterpoint

What could challenge this read

Despite the target cut, the earnings beat and strong guidance could support a short‑term rally if investors focus on the upside.

Key entities

  • company
    UnitedHealth Group

    Health‑care insurer and services provider.

  • analyst_firm
    Raymond James

    Equity research firm that lowered the price target.

Read at source← All news

StoryRaymond James cuts UnitedHealth valuation target while keeping Outperform rating

Related articles

OCT 15
$UNHMedAI 8/10

Updated Sunlight Report Reveals 2,807 Entities Across UnitedHealth Group’s Corporate Empire

The Center for Health & Democracy updated its Sunlight Report, identifying 2,807 entities under UnitedHealth Group, including 376 new ones. The report highlights UnitedHealth's $3B acquisition of Alegeus Technologies and its vast healthcare network, while noting a slowdown in acquisition growth. The report has influenced national discussions and congressional investigations.

healthcareuncovered.substack.com3 min
OCT 15
$UNHHighAI 9/10

What Happened With UnitedHealth Stock This Week?

UnitedHealth Group (UNH) shares rose 4.5% in two days, outperforming the S&P 500. Q3 2026 earnings beat estimates at $4.69 per share, while revenue matched expectations at $113 billion. The company raised its full-year 2026 earnings forecast to at least $19.50 per share, up from $18.70. Management attributed the results to strong execution across all business segments.

finance.yahoo.com2 min
OCT 15
$UNHMed

UnitedHealth (UNH) Receives a Buy from Barclays

Barclays analyst Andrew Mok maintained a Buy rating on UnitedHealth (UNH) with a $440 price target. Evercore ISI also recommended Buy, while TD Cowen kept a Hold rating. UNH reported Q2 revenue of $112.03B and net profit of $5.48B, up from last year. Insider sentiment is negative, with recent sales by executives.

theglobeandmail.com1 min
OCT 14
$UNHMed

UnitedHealth Group (UNH) Shares Rise 4.8% Amid Market Selloff on

UnitedHealth Group (UNH) rose 4.8% on October 14, 2026, despite broader market declines. The company offers a 2.33% dividend yield, a 52% payout ratio, and a 10.9% 3-year dividend growth rate. UNH's GF Score™ is 80, indicating strong fundamentals, particularly in profitability and momentum. The stock is trading 33.1% below its GF Value™ of $591.51, suggesting undervaluation.

gurufocus.com2 min
OCT 14
$UNHHighAI 9/10

UNH Stock Jumps As Earnings Beat And Guidance Hike Fuel Momentum

UnitedHealth Group (UNH) stock rose 3.91% after Q3 2026 earnings beat expectations, with adjusted EPS of $4.69 vs. $4.14 estimate. Revenue was $112.69B, slightly up from estimates. The company raised full-year 2026 adjusted EPS guidance to at least $20.50. Analysts maintained bullish stances, with Piper Sandler and TD Cowen providing mixed target adjustments. Shares jumped 4-5% post-earnings.

timothysykes.com2 min